CD19 chimeric antigen receptor-T (CAR-T) cell therapy has achieved remarkable results in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) as a new treatment with a 54.5%–92.3% complete remission (CR) rate (1–3). This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.